Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation

Faculty

Marc Carrier, MD, MSc, FRCPC
Head, Division of Hematology
Department of Medicine
The Ottawa Hospital
Professor
University of Ottawa
Senior Scientist
Ottawa Hospital Research Institute
Ottawa, Ontario
Canada

Statement of Need

Reducing barriers to adequate anticoagulation for patients with cancer improves outcomes for those with cancer-associated venous thromboembolisms (CA-VTEs).  Advances in cancer treatments and the resulting improvements in patient survival have led to an increase in the number of patients with cancer who develop a VTE at some point during their treatment (around 15%).  CA-VTE is associated with decreased survival, increased morbidity and hospitalization, and the potential delay or interruption of systemic anti-cancer therapy.  During this series, our faculty will expand clinician knowledge of VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.

In this 60-minute program, expert faculty will review CA-VTE risk factors and management strategies, discuss optimal anticoagulation therapy selection and guideline adherence, and explore approaches to working with multidisciplinary teams.  Clinicians can expect to gain valuable insight that will help them understand and overcome barriers to adequate anticoagulant therapy for patients with cancer.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify disease-, treatment-, and patient-related factors that increase the risk for CA-VTE in patients with cancer
  • Integrate available anticoagulant treatment strategies into practice that also factor in treatment duration
  • Incorporate CA-VTE management strategies aligned to the most current guidelines and evidence in patients with cancer
  • Develop strategies to coordinate care among members of the CA-VTE team, including patients, caregivers, and other HCPs, to achieve optimal adherence and CA-VTE outcomes

Financial Support

Supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Target Audience

Physicians, physician associates (PAs), nurse practitioners (NPs), and nurses specializing in oncology.

Credit Information

Jointly Accredited Provider

In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME)

Creative Educational Concepts, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to PAs: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education.

American Nurses Credentialing Center

This activity is designated for 1.00 contact hours.

American Nurses Credentialing Center with ILNA

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN, AOCNP/AOCNS, CPHON—symptom and/or side effect management; OCN, CBCN—treatment modalities; OCN, AOCNP/AOCNS, CPHON—oncologic emergencies; AOCNP/AOCNS, CPHON—coordination of care; BMTCN—early post-transplant management; CBCN—nursing practice.

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Carrier reports the following financial relationships:

Grants: Bristol Myers Squibb Company; LEO Pharma; and Pfizer Inc. (Investigator initiated trials. Payments made to OHRI)

Other financial or material support: (Honoraria received, but not taken as salary): Anthos Therapeutics; AstraZeneca; Bayer; Bristol Myers Squibb Company; Inari Medical; LEO Pharma; Pfizer Inc.; Regeneron Pharmaceuticals Inc.; Sanofi; and Valeo Pharma

 

The following individuals have no financial relationships to disclose:

Rebecca Vargas-Jackson, MD (Peer Reviewer)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.

Questions about this activity?

Call us at 859-260-1717  •  info@ceconcepts.com

GRV-025

Call us at 859-260-1717  •  info@ceconcepts.com

Cancer-Associated VTE: Balancing Risk and Reward with Modern Anticoagulation
Activity Date: 03/05/2024